DSM Asset Purchase Agreement (Details Textual) (USD $)	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Jun. 30, 2012	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
DSM Asset Purchase Agreement (Textual) [Abstract]
Number of dedicated full time equivalents for new gene libraries						3
Period for which DSM to be provided with FTEs for new gene libraries developed						1 year
Aggregate consideration received by the company						$ 37,000,000
Reimbursement for transaction related expenses incurred						2,000,000
Restricted Period of company global activities In oilseed processing						10 years
Soliciting for employment or hiring						10 years
Termination or expiration period of the transition services agreement						1 year
Gain on sale of oilseed processing business	0	0	31,278,000,000	31,278,000	31,278,000	31,278,000	0	0
Decrease in gain on sale of oilseed business due to finalization of arrangements						200,000
Increase in deferred revenue due to finalization of arrangement						200,000
Allocated license revenue for alpha-amylase and xylanase enzyme						(1,520,000)
Deferred revenue associated with undelivered elements						(1,342,000)
Deferred revenue balance						900,000
Amount recognized as revenue for DSM asset purchase agreement						$ 1,300,000